Navigation Links
Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Date:11/11/2008

BASKING RIDGE, N.J. and DURHAM, N.C., Nov. 11 /PRNewswire/ -- Regado Biosciences, Inc., today announced the appointment of Alexander R. Giaquinto, Ph.D., to the newly created position of Senior Vice President of Regulatory Affairs and Quality Assurance, effective immediately. Dr. Giaquinto brings to Regado over 35 years of experience in the pharmaceutical industry, including 30 years at Schering-Plough where he held executive management positions in the areas of Worldwide Regulatory Affairs and Compliance.

In his new position, Dr. Giaquinto will report to Dr. David J. Mazzo, Ph.D., Regado's President and Chief Executive Officer, and will be based in the Company's recently established office in Basking Ridge, New Jersey. The Company's locations in both Basking Ridge and Durham, North Carolina will have members of the executive management team and development staff.

Dr. Mazzo stated, "We are tremendously pleased to welcome someone of Dr. Giaquinto's vast experience to Regado's management team. His long-standing regulatory expertise will be essential as the Company further advances its lead therapeutic candidate, the REG1 Anticoagulation System, into late-stage clinical development." Regado recently announced completion of enrollment in the Company's Phase IIa clinical study (REVERSAL-PCI) in patients undergoing elective percutaneous coronary intervention.

Dr. Giaquinto attained the level of Senior Vice President, Worldwide Regulatory Affairs, as well as being named to a special post reporting directly to the CEO overseeing Global Compliance at Schering-Plough. These experiences, coupled with that gained as the U.S. Industry Representative of the Steering Committee of the International Conference on Harmonization (ICH), has allowed him to acquire a unique understanding of national and international regulatory processes, including regulatory submissions, reviews and approvals. At Schering-Plough, Dr. Giaquinto was instrumental in establishing the development and regulatory strategies for the approvals of 74 New Drug Applications (NDAs) and Supplements, nine Biologic License Applications (BLAs) and 28 Abbreviated NDAs.

Dr. Giaquinto currently is a Director of SemBioSys Genetics, Biothera, and PQRI. He is also a member of the Advisory Boards of Avaan Therapeutics, Allozyne Inc., Sagamore Capital and EndoCeutics, and served on, as well as chaired, the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA). Dr. Giaquinto participates in a number of charitable activities, including as Director on the Board of Trustees of the Children's Specialized Hospital and Chairman of the Board for Children's Specialized Hospital Foundation, both in Mountainside, NJ, and Chairman of the Board of Caldwell College in New Jersey. Dr. Giaquinto earned a Bachelor of Science in Pharmacy from St. John's University and a Ph.D. in Pharmaceutics from the University of Connecticut.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alexander M. Cutler Nominated for Election to DuPont Board of Directors
2. New Alexander, the Elephant Who Couldnt Eat Peanuts DVDs Help Children With Food Allergies
3. Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors
4. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
5. ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
6. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
7. Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
8. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
9. Trust for Americas Health Joins GAO in Calling for Next Administration to Focus on Urgent Public Health Issues as Top Priorities
10. Diabetes Dad Tom Karlya Rejoins Diabetes Research Institute Foundation
11. Groseth Rejoins EMSI to Lead Healthcare Services Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Gym Source, ... of a new showroom at South Dixie Hwy in Miami, FL. , “We are ... Gym Source. “The new innovative in-store concept is designed to give clients a seamless ...
(Date:1/17/2017)... Los Angeles, CA (PRWEB) , ... January 17, ... ... conflicted and concerned by the political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting ... tragedies and magical moments that help everyone endure and pass through tough times, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks ... DRTV campaigns regarding the topic of Beauty and Personal Care. , ... What better way to commit to these changes than beginning with personal care and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS West, with multiple ... new office in San Clemente, California this month. Achieve TMS West is the ... treating individuals struggling with major depression. Depression impacts over 15 million adults in ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased to ... on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more ... addition to our provider network, and the addition will benefit our members in ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... to their offering. ... The global fluoropolymer market in the healthcare industry to grow ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:1/17/2017)... Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today announced ... pharmaceutical development at Tocagen, will present at Phacilitate Cell & ... Miami . Details of the ... ... - what to do when and why Date and Time: Wednesday, ...
(Date:1/17/2017)... 2017 Research and Markets has announced the ... Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug ... 2021" report to their offering. ... The global active pharmaceutical ingredients market is ... Billion in 2016, growing at a CAGR of 6.3% from 2016 ...
Breaking Medicine Technology: